Viewing Study NCT00949650


Ignite Creation Date: 2025-12-24 @ 5:03 PM
Ignite Modification Date: 2025-12-28 @ 6:08 PM
Study NCT ID: NCT00949650
Status: COMPLETED
Last Update Posted: 2018-04-06
First Post: 2009-07-29
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Sponsor: Boehringer Ingelheim
Organization: